Nelotanserin

N/A

Report date: 2023/05/01 20:00:20
NME

Base Information

Drug NameNelotanserin
Drug Alias Namenelotanserina奈坦色林奈罗色林nelotanserinumAPD-125 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor inverse agonists
TargetsSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsREM Sleep Behavior DisorderSleep Initiation and Maintenance DisordersHallucinations +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArena Pharmaceuticals IncRoivant Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRoivant Sciences IncArena Pharmaceuticals IncSio Gene Therapies Inc
Active IndicationsN/A
Inactive IndicationsREM Sleep Behavior DisorderSleep Initiation and Maintenance DisordersHallucinations +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG